SCHEMBL3706760

SCHEMBL3706760

CCCCc1nc(C)n(-c2ncc(OC)cn2)c(=O)c1Cc1ccc(Br)cc1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
APLNR P35414 2/20 0.43
FPR1 P21462 2/20 0.36
FPR2 P25090 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NPC1 O15118 1/20 0.34
NFKB1 P19838 1/20 0.34
MAPK1 P28482 1/20 0.34
RAB9A P51151 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
GPR55 Q9Y2T6 1/20 0.34
PDE10A Q9Y233 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3704767 0.92 APLNR (0.37) APLNRL3MBTL1NPC1NFKB1MAPK1
SCHEMBL3708894 0.89 APLNR (0.35) APLNRL3MBTL1NPC1NFKB1MAPK1
SCHEMBL3710810 0.89 APLNR (0.35) APLNRL3MBTL1NPC1NFKB1MAPK1
SCHEMBL3709967 0.88 APLNR (0.38) APLNRL3MBTL1NPC1NFKB1MAPK1
SCHEMBL3708521 0.88 POLB (0.37) APLNRL3MBTL1NPC1RAB9ASMN1; SMN2
SCHEMBL3706992 0.86 APLNR (0.40) APLNRFPR1FPR2L3MBTL1NPC1
SCHEMBL3713241 0.83 APLNR (0.38) APLNRL3MBTL1NPC1NFKB1MAPK1
SCHEMBL663011 0.83 APLNR (0.40) APLNRPDE10A
SCHEMBL504759 0.82 APLNR (0.42) APLNR
SCHEMBL3702106 0.81 P2RX3 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471782-A1 NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME Kowa Company, Ltd. (JP) 2012-07-04 EP disclosed
US-20120122906-A1 NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME KOWA COMPANY, LTD. (JP) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122906-A1 NOVEL SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL PRODUCT CONTAINING SAME AGTR2, AGTR1, PPARA APLNR 268/4885FPR1 413/4885FPR2 207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.